0000950170-24-067359.txt : 20240531 0000950170-24-067359.hdr.sgml : 20240531 20240531163004 ACCESSION NUMBER: 0000950170-24-067359 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240529 FILED AS OF DATE: 20240531 DATE AS OF CHANGE: 20240531 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Inhibrx, Inc. CENTRAL INDEX KEY: 0001739614 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-42031 FILM NUMBER: 241010200 BUSINESS ADDRESS: STREET 1: 11025 N. TORREY PINES ROAD, SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: (858) 795-4220 MAIL ADDRESS: STREET 1: 11025 N. TORREY PINES ROAD, SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Inhibrx Biosciences, Inc. CENTRAL INDEX KEY: 0002007919 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 990613523 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11025 N. TORREY PINES ROAD, SUITE 140 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: (858) 795-4220 MAIL ADDRESS: STREET 1: 11025 N. TORREY PINES ROAD, SUITE 140 CITY: LA JOLLA STATE: CA ZIP: 92037 FORMER COMPANY: FORMER CONFORMED NAME: Ibex SpinCo, Inc. DATE OF NAME CHANGE: 20240111 4 1 ownership.xml 4 X0508 4 2024-05-29 true 0002007919 Inhibrx Biosciences, Inc. INBX 0001739614 Inhibrx, Inc. C/O INHIBRX BIOSCIENCES, INC. 11025 N. TORREY PINES ROAD, SUITE 200 LA JOLLA CA 92037 false false true false false Common Stock, par value $0.0001 per share 2024-05-29 4 J false 13316140 D 1157926 D On January 8, 2024, Inhibrx, Inc. ("RemainCo"), acquired 100 shares, par value $0.0001 per share (the "Common Stock"), of Inhibrx Biosciences, Inc. (the "Issuer"), which at the time constituted all of the issued and outstanding Common Stock of the Issuer. On May 29, 2024, the Common Stock was split, resulting in RemainCo's ownership of an aggregate 14,474,066 shares of Common Stock of the Issuer. On May 29, 2024 at 11:59 p.m., New York City time, RemainCo distributed approximately 92% of the Common Stock of the Issuer to the holders of record of RemainCo as of May 17, 2024. /s/ Martin Travers, Authorized Signatory on behalf of Inhibrx, Inc. 2024-05-31